Indication intelligence, analysis and sector perception

Mesoblast (MESO ASX: MSB) completes US$90 M private placement of 43 M shares

May 13, 2020 8:59am

Priced at A$3.20 per share, representing a 7% discount to both the price at the close of trading May 8, 2020 and the five-day volume weighted average price (VWAP).

MESO is trading down -$0.28 or -2.46% at $11.39

MESO has successfully completed a capital raising of US$90 million¹ (A$138 million) via a private placement of 43 million shares to existing and new institutional investors at a price of A$3.20 per share. This represents a 7% discount to both the price at the close of trading May 8, 2020 and the five-day volume weighted average price (VWAP).

The Bottom Line: A significant portion of the net proceeds will be used to scale-up manufacturing of MESO’s lead product candidate remestemcel-L for the treatment of critically ill patients suffering with diseases caused by cytokine release syndromes associated with high mortality, particularly COVID-19 acute respiratory distress syndrome (ARDS).

Proceeds will also be used for working capital and general corporate purposes.
The placement of 43 million shares represents 7.4% of MESO’s new total issued capital.

Settlement is expected to occur on Friday, May 15, 2020. New shares issued under the placement are expected to be issued and commence trading on the ASX on Monday, May 18, 2020.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

4 hours 35 min ago
RegMed Investors’ (RMi) pre-open: short week, even shorter fuse with downbeat open numbers

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.